Browse
Submit Data
Databases
API
Help

Dataset Information

171 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Anti-fungal effectors delivered by the Type VI secretion system - a proteomic analysis

ABSTRACT: Targeting a new kingdom: anti-fungal effectors delivered by the Type VI secretion system

INSTRUMENT(S): LTQ Orbitrap, Q Exactive

ORGANISM(S): Candida Albicans (yeast)

TISSUE(S): Cell Culture

SUBMITTER: julien peltier

LAB HEAD: Matthias Trost

PROVIDER: PXD006916 | Pride | 2018-05-17

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Search_analysis_TMT6_antifungal_effectors.zip	Other
	Serratia_DB10_1-5ug6h_9-12-2013_1.raw	Raw
	Serratia_DB10_1-5ug6h_9-12-2013_1oldprep.raw	Raw
	Serratia_DB10_1-5ug6h_9-12-2013_2.raw	Raw
	Serratia_DB10_1-5ug6h_9-12-2013_3.raw	Raw

Items per page:

1 - 5 of 31

Similar Datasets

Molecular weaponry: diverse effectors delivered by the Type VI secretion system.

Project description:The Type VI secretion system is a widespread bacterial nanomachine, used to deliver toxins directly into eukaryotic or prokaryotic target cells. These secreted toxins, or effectors, act on diverse cellular targets, and their action provides the attacking bacterial cell with a significant fitness advantage, either against rival bacteria or eukaryotic host organisms. In this review, we discuss the delivery of diverse effectors by the Type VI secretion system, the modes of action of the so-called 'anti-bacterial' and 'anti-eukaryotic' effectors, the mechanism of self-resistance against anti-bacterial effectors and the evolutionary implications of horizontal transfer of Type VI secretion system-associated toxins. Whilst it is likely that many more effectors remain to be identified, it is already clear that toxins delivered by this secretion system represent efficient weapons against both bacteria and eukaryotes.

| S-EPMC4832377 | biostudies-literature

Global transcriptional analysis of Cr(VI)-adapted cells of Klebsiella sp. AqSCr

Project description:Hexavalent chromium (Cr(VI)) is a highly toxic contaminant, some bacteria are able to transform it to less toxic and less soluble trivalent chromium (Cr(III)). Klebsiella sp. strain AqSCr, isolated from Cr(VI)-polluted groundwater, reduces Cr(VI) both aerobically and anaerobically, and resists up 35 mM of Cr(VI); Subculturing of AqSCr in the presence of Cr(VI) conduces to adaptation. In this study, we performed RNA-Seq of Cr(VI) adapted stage, finding 255 genes upregulated and 240 downregulated with respect to controls without Cr(VI). Genes differentially expressed are mostly associated with oxidative stress response, DNA repair and replication, sulfur starvation response, envelope-osmotic stress response, fatty acid metabolism, ribosomal subunits and energy metabolism. Among them, genes not previously associated with chromium resistance as cybB, encoding a putative superoxide oxidase, gltA2, encoding an alternative citrate synthase, and des, encoding a fatty acid desaturase were upregulated. The alternative sigma factors fecl, rpoE and rpoS were upredgulated in Cr(VI) adapted cells, then they participate in orchestate the Cr(VI)-resistance mechanisms in AqSCr strain

2021-05-20 | GSE160968 | GEO

Juvenile Fundulus heteroclitus exposed to Cr(VI)

Project description:Cr(VI) is a common bioavailable toxic metal that can cause oxidative stress, DNA adducts, and perturb normal gene expression. Changes in gene expression are useful biomarkers of toxicant exposure that provide information about the health of an organism, its ability to adapt to its environment, and indicate potential toxicant-specific effects. Therefore, we developed a toxicology array to the estuarine sentinel species Fundulus heteroclitus, or mummichog. Juvenile mummichog were exposed to potassium dichromate for thirty days at concentrations from 0 to 24 mg/L of Cr(VI), and growth was measured to determine the NOEC (1.5 mg/L or 0.0288 mM) and LOEC (3 mg/L or 0.0577 mM). Body burdens from Cr(VI) exposed fish demonstrated a dose dependent increase and were inversely correlated to body weight. Cr(VI)-exposed juvenile mummichog differentially expressed greater than 20 genes in a dose-dependent manner, including hepatic glucose transporter 2, liver fatty acid binding protein, ATPase synthase 8, type II keratin, TBT binding protein, and complement component C3-2. Many of these genes are involved in energy metabolism or growth, which is consistent with the reduced growth caused by Cr(VI). Keywords: dose response

2006-03-31 | GSE3481 | GEO

side-VI

Project description:Drosophila melanogaster side-VI, sidestep VI, is differentially expressed in 1 experiment(s);

| FBgn0083950 | ExpressionAtlas

side-VI

Project description:Drosophila melanogaster side-VI, sidestep VI, is expressed in 4 baseline experiment(s);

| FBgn0083950 | ExpressionAtlas

beat-VI

Project description:Drosophila melanogaster beat-VI, beaten path VI, is expressed in 3 baseline experiment(s);

| FBgn0039584 | ExpressionAtlas

beat-VI

Project description:Drosophila melanogaster beat-VI, beaten path VI, is differentially expressed in 7 experiment(s);

| FBgn0039584 | ExpressionAtlas

Adult male Fundulus heteroclitus exposed to Cr(VI)

Project description:Cr(VI) is a common bioavailable toxic metal that can cause oxidative stress, DNA adducts, and perturb normal gene expression. Changes in gene expression are useful biomarkers of toxicant exposure that provide information about the health of an organism, its ability to adapt to its environment, and indicate potential toxicant-specific effects. Therefore, we developed a toxicology array to the estuarine sentinel species Fundulus heteroclitus, or mummichog. Adults males were exposed to Cr(VI) for 7-days at 0, 1.5 (NOEC), or 3 mg/L (LOEC). Livers were excised and RNA isolated. Adults are used in the laboratory experiments so that we can compare laboratory studies to fish caught at chromium-contaminated field sites. Cr(VI) altered the expression of 12 genes in adult liver, including hepatic growth factor activator, heart fatty acid binding protein, and complement component C3-2. Keywords: dose response

2006-03-31 | GSE3480 | GEO

VI-28 treatment induced alteration of gene expression in human lymphocytes

Project description:The aim of the present study was to evaluate whether Chinese herbs VI-28 has any potential effect on the immune system in a human cell culture system. An inflammatory cDNA array was used in the study to analyze the profile of gene expression in cells treated by VI-28. Keywords: other

2006-06-12 | GSE1748 | GEO

Collagen type VI regulates TGFβ bioavailability in skeletal muscle

Project description:Collagen VI-related disorders (COL6-RDs) are a group of rare muscular dystrophies caused by pathogenic variants in collagen VI genes. ¬¬Collagen type VI is a heterotrimeric, microfibrillar component of the muscle extracellular matrix (ECM), predominantly secreted by resident fibroadipogenic precursor cells in skeletal muscle. Collagen VI absence or mislocalization in the skeletal muscle ECM underlies the non-cell autonomous dystrophic changes and dysfunction in skeletal muscle in COL6-RDs with an as of yet elusive direct mechanistic link between the ECM and myofiber dysfunction. Here, we derive a novel mouse model of COL6-RD, Col6a2-/- mice, and conduct a comprehensive natural history study in male and female animals aged to 60 weeks of age. Col6a2-/- mice have a normal lifespan but develop muscle weakness based on standardized behavioral tests (grip and hanging wire test), muscle atrophy with histologic hallmarks of muscular dystrophy, and reduced muscle force prodcution on physiologic parameters. We also report a robust dysregulation of TGFβ pathway early in the disease process and thus propose a new mechanism for pathogenesis of the disease that links the ECM regulation of TGFβ with downstream skeletal muscle abnormalities, paving the way for developing therapeutics that target this pathway.

2023-12-04 | GSE228223 | GEO